Brogan Pharmaceuticals, Inc
is a firm dedicated to the development and commercialization of
pharmaceutical and
biological products for the purpose of treating and diagnosing rare
diseases.
September 2006
Brogan is one of five
companies selected by the National Institute of Health and National Cancer
Institute to present a promising cancer therapy to a multi agency taskforce.
The task force consists of representatives from the National Cancer
Institute (NCI), Food and Drug Administration (FDA), and Centers for
Medicare and Medicaid Services (CMS) to expedite the process of bringing the
new product to market. The program provides advice from a multi agency
perspective on the spectrum of scientific, regulatory, and reimbursement
issues related to developing imaging devices or technology.
May 2006
Indiana Governor's strategic plan includes companies in high growth, high
technology fields. Local firm gets state tech
grant.
BY PATRICK GUINANE
pguinane@nwitimes.com
317.637-9078
A Crown Point bioscience firm has won a $500,000 state
grant to help bring to market a drug aimed at helping doctors better
diagnosis a cancer that afflicts young children and a tumor that causes high
blood pressure and strokes in adults.
Indiana 21st Century Fund awards Brogan
Pharmaceuticals
Inside Indiana Business interview with Gary Dick highlights Brogan
Pharmaceuticals with Indiana Economic Development Dir. of Entrepreneurship,
Bruce Kidd.
April 2006
CROWN POINT | Announced April 15th, Dr. Stephen Byrn PhD. has been
appointed to the Brogan Pharmaceuticals Board of Technical Advisors.
Dr. Byrn is the Charles B. Jordan Professor of Medicinal Chemistry, and
Head, Department of Industrial and Physical Pharmacy at Purdue University.
He is a current consultant to various Pharmaceutical companies and the FDA.
Dr. Byrn was formerly a member and
chair of the Pharmaceutical Sciences Advisory Committee, FDA, and USP
Council of Experts.
CROWN POINT | Announced April 15th, Dr. Mark Green PhD. has been
appointed to the Brogan Pharmaceuticals Board of Technical Advisors.
Dr. Green is the Head of the Division of the Nuclear Pharmacy, Department of
Industrial and Physical Pharmacy at Purdue University. Dr. Green is a
recognized leader and researcher in the field of radiochemistry and
radiopharmaceutical product development. Dr. Green currently serves on
various advisory boards and as a consultant to pharmaceutical industry
leaders.
CROWN POINT | Announced April 12th, Brogan expands production capacity for OmaClear™, Iobenguane I-123 due to
anticipated changes in initial demand post FDA approval. "City officials have scored an economic development
coup", announcing Tuesday that a Purdue Technology Center pharmaceutical
company will locate its manufacturing facility in Millennium Park.
Mayor Dan Klein said. "There's been a lot of talk of seeing our kids staying
in the State of Indiana. This is monumental for us to allow that to happen."
March 2006
Brogan Pharmaceuticals receives 21st Century Fund award to finalize and
file the company's first FDA New Drug application, OmaClear™.
December 2005
Brogan Pharmaceuticals takes 1st Place, outpacing over 100 other entrants
in the Eli Lilly Endowment "Opportunity for Indiana" Business Plan
competition. The business plan and model seek to reduce the overall
time and cost to developing diagnostic and therapeutic radiopharmaceuticals
through novel regulatory and clinical development pathways.
October 2005
Brogan Pharmaceuticals achieves FDA orphan drug status for
OmaClear™, Iobenguane Sulfate I123 , a
radiopharmaceutical to be utilized in the diagnosis and staging of
neuroblastoma and pheochromocytoma.
August 2005
Brogan Pharmaceuticals, offers three interns the opportunity
to be a part of the regulatory development of the products first
radiopharmaceutical.
April 2005
WorkOne, US Dept. of Labor and Brogan Pharmaceuticals
collaborate on recruitment, technical training for current Good
Manufacturing Practices.
February 1, 2005
Brogan Pharmaceuticals moves into their business
development offices located at the
Purdue University Technology Center &
Research Park, Crown Point, IN.
January 2005
Brogan Pharmaceuticals completes and files first of two SBIR and SBIR
contract proposals with National Institute of Health.
